Skip to main content
Livermore
Livermore
ZHEN

Octagon Capital Advisors LP

SEC CIK
0001839435
Latest filing
Aug 14, 2026

The latest 13F from Octagon Capital Advisors LP covers Q2 2026 (filed Aug 14, 2026): 26 long positions worth $1.09B. The top 10 holdings make up 80.2% of the portfolio, and the largest is Dianthus Therapeutics, Inc. (DNTH) at 16.5%. Livermore has 23 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
4
Est. +$44.3M
Added
4
Est. +$81.9M
Reduced
6
Est. −$64.2M
Sold out
7
Est. −$106.3M

Top 5 holdings

Share of this quarter's portfolio value

  1. DNTHDianthus Therapeutics, Inc.
    16.5%$179.5MHistory
  2. DFTXDefinium Therapeutics, Inc.
    12.7%$138.8MHistory
  3. ABVXAbivax S.A.
    12.1%$132.3MHistory
  4. COGTCogent Biosciences, Inc.
    8.3%$90.9MHistory
  5. ALMSAlumis Inc.
    7.3%$79.7MHistory

Share of portfolio

Top 5 holdings and the other 21 positions, by share of portfolio value

  1. DNTH16.5%
  2. DFTX12.7%
  3. ABVX12.1%
  4. COGT8.3%
  5. ALMS7.3%
  6. Other 21 positions43.0%

Biggest buys

New and added positions, by estimated amount bought

  1. ABVXAbivax S.A.
    +$42.1MAddedHistory
  2. DFTXDefinium Therapeutics, Inc.
    +$24.0MAddedHistory
  3. SMMTSummit Therapeutics Inc.
    +$18.2MNewHistory
  4. ANLAdlai Nortye Group Ltd.
    +$10.7MNewHistory
  5. PHVSPharvaris N.V.
    +$10.1MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. DFTXDefinium Therapeutics, Inc.
    +7.63 pp5.1% → 12.7%History
  2. ABVXAbivax S.A.
    +3.80 pp8.3% → 12.1%History
  3. TSHATaysha Gene Therapies, Inc.
    +1.68 pp4.4% → 6.1%History
  4. SMMTSummit Therapeutics Inc.
    +1.67 pp0.0% → 1.7%History
  5. ANLAdlai Nortye Group Ltd.
    +0.99 pp0.0% → 1.0%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. CNTACentessa Pharmaceuticals plc
    −$29.8MSold outHistory
  2. KALVKalVista Pharmaceuticals, Inc.
    −$29.2MSold outHistory
  3. TERNTerns Pharmaceuticals, Inc.
    −$27.9MSold outHistory
  4. TRVITrevi Therapeutics, Inc.
    −$21.8MReducedHistory
  5. KYMRKymera Therapeutics, Inc.
    −$13.2MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. CNTACentessa Pharmaceuticals plc
    −3.30 pp3.3% → 0.0%History
  2. KALVKalVista Pharmaceuticals, Inc.
    −3.23 pp3.2% → 0.0%History
  3. TERNTerns Pharmaceuticals, Inc.
    −3.09 pp3.1% → 0.0%History
  4. DNTHDianthus Therapeutics, Inc.
    −1.60 pp18.1% → 16.5%History
  5. TRVITrevi Therapeutics, Inc.
    −1.42 pp2.0% → 0.5%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$1.09B
+$185.9M (+20.6%) vs. prior quarter
Positions
26
−3 vs. prior quarter
Top 10 concentration
80.2%
Top 10 as share of value
Turnover
12.7%
Q2 2026, one quarter
Average holding period
6.1 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $1.09B (Q2 2026)

Q1 2021: $265.5MQ2 2021: $482.8MQ3 2021: $406.1MQ4 2021: $513.9MQ1 2022: $462.6MQ2 2022: $374.7MQ3 2022: $579.4MQ4 2022: $642.2MQ1 2023: $693.4MQ2 2023: $716.7MQ3 2023: $568.0MQ4 2023: $625.0MQ1 2024: $822.6MQ2 2024: $606.1MQ3 2024: $623.9MQ4 2024: $587.1MQ1 2025: $460.1MQ2 2025: $455.3MQ3 2025: $640.2MQ4 2025: $798.8MQ1 2026: $903.6MQ2 2026: $1.09B
Q1 2021Q2 2026
13F filings of Octagon Capital Advisors LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202626$1.09BDNTHDFTXABVXvs. Q1 2026SEC
Q1 2026May 15, 202629$903.6MDNTHCOGTABVXvs. Q4 2025SEC
Q4 2025Feb 17, 202626$798.8MABVXDNTHCOGTvs. Q3 2025SEC
Q3 2025Nov 14, 202526$640.2MABVXDNTHGOSSvs. Q2 2025SEC
Q2 2025Aug 14, 202530$455.3MDNTHAVBPVRNAvs. Q1 2025SEC
Q1 2025May 16, 2025Amended34$460.1MAPLSDNTHAVBPvs. Q4 2024SEC
Q4 2024Feb 14, 202531$587.1MAPLSAVBPDNTHvs. Q3 2024SEC
Q3 2024Nov 14, 202441$623.9MAPLSVRNAGPCRvs. Q2 2024SEC
Q2 2024Aug 14, 202444$606.1MAPLSDNTHGPCRvs. Q1 2024SEC
Q1 2024May 15, 202456$822.6MAPLSALPNDNTHvs. Q4 2023SEC
Q4 2023Feb 14, 202433$625.0MAPLSCBAYVRNAvs. Q3 2023SEC
Q3 2023Nov 14, 202335$568.0MAPLSROIVCBAYvs. Q2 2023SEC
Q2 2023Aug 14, 202340$716.7MAPLSVRNACBAYvs. Q1 2023SEC
Q1 2023May 15, 202335$693.4MAPLSKDNYVRNAvs. Q4 2022SEC
Q4 2022Feb 14, 202332$642.2MAPLSKDNYVRNAvs. Q3 2022SEC
Q3 2022Nov 14, 202235$579.4MAPLSRCUSKDNYvs. Q2 2022SEC
Q2 2022Aug 15, 202220$374.7MAPLSRCUSKDNYvs. Q1 2022SEC
Q1 2022May 16, 202224$462.6MAPLSRCUSCLDXvs. Q4 2021SEC
Q4 2021Feb 14, 202228$513.9MAPLSRCUSNBPvs. Q3 2021SEC
Q3 2021Nov 15, 202130$406.1MNBPAPLSCLDXvs. Q2 2021SEC
Q2 2021Aug 16, 202134$482.8MAPLSNBPCRISvs. Q1 2021SEC
Q1 2021May 17, 202128$265.5MNBPCRISAPLS–SEC

13D and 13G filings

Companies where Octagon Capital Advisors LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

2 companies, largest stake first.

Companies where Octagon Capital Advisors LP owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
DTILPrecision Biosciences Inc13G9.99%2.33M sharesNewFeb 10, 20261 filingFeb 10, 2026SEC
PALIPalisade Bio, Inc.13G6.40%9.57M sharesNewFeb 10, 20261 filingFeb 10, 2026SEC

Latest filings

31 filings on file made by Octagon Capital Advisors LP or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Octagon Capital Advisors LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
CNTXContext Therapeutics Inc.Jul 31, 20264:01 PM ET13G/A3.30%3.05M shares−2.40 ppfrom 5.70%Below 5%Jun 30, 2026SEC
GOSSGossamer Bio, Inc.May 14, 20264:01 PM ET13G/A3.80%8.98M shares−2.70 ppfrom 6.50%Below 5%Mar 31, 2026SEC
DNTHDianthus Therapeutics, Inc.May 14, 20264:01 PM ET13G/A3.60%1.95M shares−2.50 ppfrom 6.10%Below 5%Mar 31, 2026SEC
CRBPCorbus Pharmaceuticals Holdings, Inc.May 14, 20264:01 PM ET13G/A0.00%0 shares−5.40 ppfrom 5.40%Below 5%Mar 31, 2026SEC
CNTXContext Therapeutics Inc.May 14, 20264:01 PM ET13G5.70%5.25M sharesNewMar 31, 2026SEC
GOSSGossamer Bio, Inc.Feb 17, 20264:02 PM ET13G/A6.50%15.1M shares−2.10 ppfrom 8.60%Dec 31, 2025SEC
DTILPrecision Biosciences IncFeb 10, 20261:15 PM ET13G9.99%2.33M sharesNewDec 31, 2025SEC
UNCYUnicycive Therapeutics, Inc.Feb 10, 20261:15 PM ET13G/A4.70%1.00M shares−1.00 ppfrom 5.70%Below 5%Dec 31, 2025SEC
CRBPCorbus Pharmaceuticals Holdings, Inc.Feb 10, 20261:14 PM ET13G/A5.40%955.0K shares–Dec 31, 2025SEC
PALIPalisade Bio, Inc.Feb 10, 20261:13 PM ET13G6.40%9.57M sharesNewDec 31, 2025SEC
UNCYUnicycive Therapeutics, Inc.Nov 14, 20254:46 PM ET13G/A5.70%1.00M shares−2.10 ppfrom 7.80%Sep 30, 2025SEC
TSHATaysha Gene Therapies, Inc.Nov 14, 20254:46 PM ET13G/A3.30%9.07M shares−1.80 ppfrom 5.10%Below 5%Sep 30, 2025SEC
DNTHDianthus Therapeutics, Inc.Nov 14, 20254:46 PM ET13G/A6.10%2.42M shares−1.00 ppfrom 7.10%Sep 30, 2025SEC
AVBPArriVent BioPharma, Inc.Nov 14, 20254:46 PM ET13G/A4.90%1.97M shares–Below 5%Sep 30, 2025SEC
UNCYUnicycive Therapeutics, Inc.Aug 12, 20254:05 PM ET13G/A7.80%1.00M shares–Jun 30, 2025SEC
GOSSGossamer Bio, Inc.Feb 5, 20256:28 PM ET13G8.60%19.6M sharesNewDec 31, 2024SEC
TSHATaysha Gene Therapies, Inc.Feb 5, 20256:05 PM ET13G5.10%10.4M sharesNewDec 31, 2024SEC
DNTHDianthus Therapeutics, Inc.Feb 5, 20255:42 PM ET13G/A7.10%2.11M shares–Dec 31, 2024SEC
OKUROnKure Therapeutics, Inc.Oct 28, 202413G/AOld format–––SEC
UNCYUnicycive Therapeutics, Inc.Oct 11, 202413GOld format–New–SEC